Compare Datadog Inc (DDOG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Medpace Holdings Inc — how do they compare? Datadog Inc trades at $292.1 (market cap $98.31B), while Medpace Holdings Inc trades at $614.63 (market cap $16.82B). The key difference: Datadog Inc is far larger — about 5.8× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 2,936,660). Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Medpace Holdings Inc for 14 Days on average.
| DDOG | MEDP | |
|---|---|---|
Market Cap | $98.31B | $16.82B |
Volume | 2,936,660 | 223,093 |
Sector | Technology | Health |
52-Week High | $288.15 | $630.19 |
52-Week Low | $102.62 | $393.42 |
Typical Hold Time | 76 Days | 14 Days |
Enterprise Value | $94.61B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $290.26, up 6.97% with strong bullish momentum approaching 52-week highs. The stock shows robust revenue growth reaching $3.43B in 2025, though profitability metrics remain mixed with a high P/E ratio of 547.6. Recent earnings beats and accelerating enterprise customer expansion support positive sentiment, while technical indicators show the stock trading near resistance at $288 with strong moving average support.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and AI-driven growth catalysts, though elevated valuation and negative cash flow trends present risks. The $276.10 consensus price target suggests limited upside from current levels, requiring continued execution on enterprise expansion and margin improvement to justify premium valuation.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
